**Author details**

Laura-Ancuta Pop1 , Oana Zanoaga1 , Paul Chiroi1 , Andreea Nutu1 , Schuyler S. Korban2 , Cristina Stefan3,4, Alexandru Irimie5 and Ioana Berindan-Neagoe1 \*

1 Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

2 Department of Natural Resources and Environmental Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA

3 SingHealth Duke-NUS Global Health Institute (SDGHI), Duke-NUS Medical School, Singapore

4 African Medical Research and Innovation Institute, Cape Town, South Africa

5 Department of Surgical Oncology and Gynecological Oncology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania

\*Address all correspondence to: ioananeagoe29@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**75**

*Microarrays and NGS for Drug Discovery DOI: http://dx.doi.org/10.5772/intechopen.96657*

[1] Doroshow JH, Kummar S. Translational research in oncology--10 years of progress and future prospects. Replace with: Nat. Rev. Clin. Oncol.

[10] Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science. 2009;

[11] Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing Drug Discovery via Artificial Intelligence. Trends Pharmacol. Sci. 2019;40(8):

[12] Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat. Rev. Drug Discov. 2006;

[13] Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health affairs.

[14] Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical Care

[15] Prasad S, Gupta SC, Aggarwal BB. Serendipity in Cancer Drug Discovery: Rational or Coincidence? Trends Pharmacol. Sci.. 2016;37(6):435-50.

Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev.

[16] Workman P, Antolin AA, Al-Lazikani B. Transforming cancer drug discovery with Big Data and AI. Expert Opin Drug Discov. 2019;

[17] Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. New England J. Med. 2015;372(21):2018-28.

[18] Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology educational book

14(11):1089-95.

2020 Jul;29(7):1304-1312.

325(5937):161-5.

592-604.

5(12):993-6.

2006;25(2):420-8.

[2] Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, et al. Cancer drug development: The missing links. Exp. Biol. Med.

[3] Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;

[4] Roy PS, Saikia BJ. Cancer and cure: A critical analysis. Indian J. Cancer.

[5] Bordoloi D, Sailo, B.L., Manteghi, N., Padmavathi, G., Kunnumakkara, A.B. Introduction and basic concepts of cancer. Cancer Cell Chemoresist.

[6] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2018;

Parkin DM, Piñeros M, et al. Estimating

mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;

[8] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309.

[9] Eder J, Herrling PL. Trends in Modern Drug Discovery. Handbook of

Exp. Pharmacol. 2016;232:3-22.

the global cancer incidence and

2014;11(11):649-62.

**References**

2019;244(8):663-89.

74(9):2377-84.

2016;53(3):441-2.

Chemosensit. 2018.

68(6):394-424.

144(8):1941-53.

[7] Ferlay J, Colombet M, Soerjomataram I, Mathers C, *Microarrays and NGS for Drug Discovery DOI: http://dx.doi.org/10.5772/intechopen.96657*
